Hypoxia-targeted Radiotherapy Boost for GBM
NCT: NCT07769918 · NOT_YET_RECRUITING
Brief Summary
The purpose of this study is to evaluate the use of dynamic contrast-enhanced MRI (DSC-MRI) to identify and target hypoxic tumor regions in glioblastoma (GBM). The study is divided into two phases: Phase 1 will focus on biologic validation in newly diagnosed GBM patients, while Phase 2 will assess the clinical implementation of DSC-MRI-guided radiotherapy in recurrent or postoperative GBM patients. The primary endpoints are the validation of DSC-MRI in identifying hypoxic regions and assessing the safety and efficacy of radiation therapy based on these findings.
Frequently Asked Questions
What is Hypoxia-targeted Radiotherapy Boost for GBM?
Hypoxia-targeted Radiotherapy Boost for GBM is a clinical trial registered under NCT07769918. Current status: NOT_YET_RECRUITING.
What is the status of NCT07769918?
The current status of NCT07769918 (Hypoxia-targeted Radiotherapy Boost for GBM) is: NOT_YET_RECRUITING.
When did Hypoxia-targeted Radiotherapy Boost for GBM start?
Hypoxia-targeted Radiotherapy Boost for GBM started on 2026-09-01.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.